Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma

Recurrent Glioblastoma Clinical Trial

Official title:

Neoadjuvant PD-1 Antibody Alone or Combined With Autologous Glioblastoma Stem-like Cell Antigens-primed DC Vaccines (GSC-DCV) for Patients With Recurrent Glioblastoma：A Phase II, Randomized Controlled, Double Blind Clinical Trial.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04888611
• Other study ID #: KY2021-547
• Status: Recruiting
• Phase: Phase 2
• Start date: October 26, 2021
• Est. completion date: May 1, 2024

Study information

• Verified date: November 2021
• Source: Huashan Hospital
• Contact: Yu Yao, MD
• Phone: 86-021-52889999
• Email: yu_yao[@]fudan.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Glioblastoma multiforme (GBM) are the most prevalent malignant tumor in central nervous system. At recurrence, no clear standard-of-care therapy is agreed for recurrent GBM (rGBM) and median overall survival is estimated to rarely exceed 6-9 months with effective therapies. Neoadjuvant therapy with anti-PD-1 monoclonal antibodies were confirmed to be helpful to extend survival in rGBM. Vaccine, dendritic cells (DCs) pulsed with glioblastoma stem-like cell (GSC) antigens (GSC-DCV), could extend survival for GBM patients in our previous clinical study (PMID: 30159779). The purpose of this study is to evaluate the safety and efficiency of using the neoadjuvant therapy with PD-1 antibody (Carilizumab) plus DC vaccine (GSC-DCV) in patients with recurrent glioblastoma.

Description:

This is a phase II randomized controlled clinical study. The purpose of this research is to study the safety and efficacy of Camrelizumab alone or combined with GSC-DCV vaccines in treating patients with recurrent glioblastomas. The participants will be randomly assigned into two group. Patients in group A will receive neoadjuvant Camrelizumab (PD-1 antibody), followed by surgical resection, DC vaccines and further PD-1 inhibitor treatment until toxicity or progression. Patients in group B will receive neoadjuvant Camrelizumab (PD-1 antibody), followed by surgical resection, placebo and further PD-1 inhibitor treatment until toxicity or progression. Furthermore, to evaluate the associations between exploratory biomarkers, clinical outcomes, and adverse events based on the next generation sequencing.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: May 1, 2024
• Est. primary completion date: May 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Age from 18 to 70 years.

2. Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2.

3. Estimated life expectancy > 3 months.

4. Previous first-line therapy with radiotherapy and chemotherapy, first or second relapse with unequivocal evidence of tumor progression.

5. Pathological diagnosis or molecular diagnosis for lesion this time was confirmed to be recurrent brain glioma (WHO grade 4).

6. Patients with subtotal resection or above of the tumor confirmed with contrast MR within 72 hours after surgery.

7. No high-dose systemic corticosteroids (defined as >10 mg day-1 of prednisone or bio-equivalent for at least seven consecutive days before administration).

8. No antibiotics for at least three consecutive days before administration.

9. Adequate organ function defined by:

Adequate bone marrow reserve: absolute neutrophil (segmented and bands) count (ANC) = 1.0×10^9/L, platelets =100×10^9/L; hemoglobin = 8 g/dL. Hepatic: bilirubin 2×upper limit of normal (ULN), aspartate transaminase (AST) and alanine transaminase (ALT) < 2.5×upper limit of normal (ULN). Renal: Normal serum Creatinine for age (below) or creatinine clearance >60 ml/min/1.73 m2. Electrocardiogram: normal.

10. Written informed consent.

11. Patient should have good follow-up compliance.

Exclusion Criteria:

1. Pregnant or breast-feeding patients.

2. Patients with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements.

3. Patients with history of immune system abnormalities such as hyperimmunity (e.g., autoimmune diseases) and hypoimmunity (e.g., myelodysplastic disorders, marrow failures, AIDS, ongoing pregnancy, transplant immuno-suppression), or medication of cortisol.

4. Patients with any conditions that could potentially alter immune function (e.g., AIDS, multiple sclerosis, diabetes, renal failure).

5. Any previous investigational medication within 30 days before first administration of Camrelizumab.

6. History of allergy to study drug components or of severe hypersensitivity reactions to any monoclonal antibodies.

Related Conditions & MeSH terms

• Glioblastoma
• Recurrent Glioblastoma

Intervention

Biological:
• Camrelizumab plus GSC-DCV
Prior to scheduled surgery, patients need to receive Camrelizumab IV (3mg/kg, up to 200mg). After surgery, patients receive Camrelizumab IV (3mg/kg, up to 200mg) and GSC-DCV IH every 3 weeks in the absence of disease progression or unacceptable toxicity.
• Camrelizumab plus Placebo
Prior to scheduled surgery, patients need to receive Camrelizumab IV (3mg/kg, up to 200mg). After surgery, patients receive Camrelizumab IV (3mg/kg, up to 200mg) and Placebo IH every 3 weeks in the absence of disease progression or unacceptable toxicity.

Locations

Country	Name	City	State
China	Huashan Hospital, Fudan University	Shanghai	Shanghai

Sponsors (3)

Lead Sponsor	Collaborator
Huashan Hospital	Jiangsu HengRui Medicine Co., Ltd., Shanghai Sunstem Biotechnology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Exploratory biomarkers	To investigate the association between biomarkers and clinical outcomes using diverse biospecimen based on the next generation sequencing, including ctDNA, TIL (tumor infiltrating lymphocyte) density and TCR (T cell receptor) Clonality, gene expression signature, genomic mutation, microbial bacteria and so on.	24 months
Primary	Overall survival (OS)	Time from enrollment to the dates of death from any cause or last follow up reported	24 months
Primary	Progression-free survival (PFS)	Time from enrollment to the dates of disease progression, death from any cause or last tumor assessment reported between date of first patient enrollment	12 months
Secondary	Number of treatment-related adverse events	Toxicity assessed by Common Terminology Criteria for Adverse Events	12 months
Secondary	Treatment Responses Rate	Response rate assessed by immunotherapy Response Assessment for Neuro-Oncology (iRANO) criteria	6 months